1 '1615 UMU RSET PEMBNA LAPORAN AKHlR AN PTE KDOK 2011 Kadar P selectin, ADAMTS 13 dan Faktor Von Willebrand pada gangguan hemostasis penderita leptos...
E·mwl. �c,b:tn'!'·litb:.:ug d.:pk<.:�.�n td II d,,,,,. . http> "\1 ,,.,\
}nh:mg.d.:pk.:s.ct11.1J
KEPUTUSAN KEPALA BADAN PENEUTIAN DAN PENGEMBANGAN KESEHATAN NOMOR: HK.03.05/2/1273/2012 TENTANG PENETAPAN TIM PELAKSANA RISET PEMBINAAN ILMU PENGETAHUAN DAN TEKNOLOGI KEDOKTERAN TAHUN 2012 KEPALA BADAN PENELITIAN DAN PENGEMBANGAN KESEHATAN, Menimbang
:
a. bahwa
untuk
ka pasitas
meningkatkan di
peng embangan
bidang
penelitian
kesehatan
perlu
dan
dilakukan
pembinaan kepada para penelili muda; b.
bahwa
peneliti
dalam muda
rangka pembinaan dan menggal1 potens:
perlu
diiakukan
Rrset
Pembinaan
llmu
Pengetanuan dan Teknologi Kedokteran. c
bahwa berdasarkan pertimbangan sebagaimana dimaksud pada huruf a dan b perlu ditetapkan Keputusan Kepala Badan Penelitian dan Pengembangan Kesehatan tentang PembentlJkan
Tirn
Pelaksana
R1set
Pembinaan
P engelah uan dan Teknologi Kedokteran Tahun
Mengingat
2012,
llrnu
1. Undang-Undang Nomor 18 Tahun 2002 ten tang Sistem Penerapan llrnu
Nasional Penelitian, Pengembangan dan
Pengetal1uan dan Teknologi (Lembaran Negara Republik Indonesia
Tat11.m
2002
Nomor
!34, Tambat1an l .embaran .
Negara Hepublil< lndones1a Nomor 421 9); 2. Undang-Undang Nomor 36 Tahun (lembaran
Negara Tah un
Lembaran Negara Nomor 3.
Peraturan Penelittan Neg ara
Pernenntah dan
Republik
2009 5063).
Nomor
Indonesia
Nomor
39
Pengembangan
Tambahan I emba ran
2009 tentang 144,
Tahun
1995
Kesehatan
Tah un
Kesehatan Tambahan
1995
tentang
(Lembaran Nomor
67.
Negara Republik lndonesrn Nomor
3609): 4.
Peraturan Presiden Nornor 76 Tahun 2011 Perubu�lan atas Peraturan
Presiden
N omor
47
Tahun
2009
Pembentukan dan Organisasi Kementena n Negara.
Tentang
J:d:ill P.:orc..:w�a11 Nl:�ara N,,_ 29 Jak1nta 10561.1 Ko1ak Pus 122o
Tekplln: t021) -+26101\l\ Fabimik. (0.21 i -1�4.\l.l3.>
PENGEMBANGAN f<ESEHATAN TENT,..\NG TIM flELAKSANI\
RISET PEMBINAAN ILMU PENGETAHUAN DAN TEKNOLOGI KEDOKTERAN TAHUN 2012: KESATU
Tim
Pelaksana
Riset
Pemb1naan
llmu
Pengetahuan dan
Teknologi Kedokteran Tarwn 2012 (selanjutnya disebut Risbin lptekdok
2012)
sebagaimana
tercantum
dalam
lampiran
keputusan ini bertugas:
1.
2.
Melaksanakan penelitian sesuai kaidah ilrniah dan etika
dengan waktu yang telah diletapkan; Mempertanggungjawabkan penggunaan
anggaran
sesuai
peraturan yang berlaku:
3.
Membuat dan menyampaikan laporan kemajuan dan laporan
4
Mernbuat ringkasan eksekutif berdasarkan has1l ponelltian
akhir penelitian: sebaga1 bahan masukan kepadtl
pengarnb1lan keputusan
dan pengelola progr<.�m yang terkalt c!enq:.�n ha s il penc:lillfm
KEDUA
Tim
Pelaksana
R1sbin
lptekdok
Tahun
2012 sebaga1rnona
dimaksud pada diktum kesatu diberikan honor sesuai dengan
ketentuan yang berlaku: KETIGA
Dalam melaksanakan tugasnya, Tim· Pelaksana �·!1Sb1n lptekdok
Tahun 2012 berpedoman pada pera1uran perundann-undangan yang berlaku, KEEMPAT
Dalam melaksanakan tugasnya. Tim Pelaksana Risbin lptekdok Tahun 2012 dapat berkonsultasi dan berkoordinasi dengan Tim Panel Pakar dan Tim Pengeloia Administrasi Risb1n lptekdok.
KELIMA
Biaya kegiatan Tim Pelaksan<:1 Risbm lpt ek dok Tr�hun 2012 dibebankan pada DIPA Sekrelanat Badan Litbangkes tahun anggaran 2012 Nomor
l�itp: '\\''.\\\·.hHx-�n!:'.d(:p k t'' t!'-1.1d ..
berlakunya Keput usan ini, maka Keputusan Kepala Penelitian
dan
HK.03.05/11393/2011
Pengembangan
Tanggal
19
Kesehatan
Janua ri
2011
Nomor
ten!ang
Penetapan Tim Pelaksana Riset Pembinaan llmu Pengetahuan
dan Teknologi K edokteran Tahun 2011 dinyalakan tidak bedaku lagi: KETUJUH
Keputusan ini berlaku sejak tanggal ditetapkan.
j
Oitetapkan di Jakarta Pa d
tan gal17 FEBRUARI2012
Kep�
-' ';7 /
E:
T
LAMPiRAN KEPUTUSAN KEPALA BAOAN LITBANG KESEHATAN NOMOR : HK 03.05/V1273/2012 TANGGA1. : 17 Februarf 2012 SUSUNAN TIM PELAKSANA RISET PEMBINAAN ILMU PENGETAHUAN DAN TEKNOLOOI KEOOKTERAN (RISBIN IPTEKDOK) 2012
·:, J
BALAI LITBANG, BP2 GAJ
Sri Nuryani Wa'>y�nrngrum. SSi R
The ELISA Kit is to be used for quantitative determination of Human
Von Wiflebrand Factor (vWF) in serum, Plasma and other biological fluids. Kit is intended for research use only not for diagnostics.
1 . Principles of Method
The Human vWF ELISA Kit is an Vitro enzyme-linked imm unosorbent assay for the quantitative
measurement
of
Human
vWF
in
serum,
plasma.
tissue.cell
culture
supernatants and urine. The Human vWF polyclonal antibodies are precoated onto 96-well plate. Standard and samples are pipetted into the wells and Human vWF present in a sample is bound to the wells by the i mmobilized antibody. The biotinylated detection antibodies are added to the wells and then followed by washing with PBS or TBS buffer. After washing away unbound biotinylated antibody, Avidin-Biotin -Peroxidase Complex is pipetted to the wells. The wells are washed again,
a TMB substrate solution is added to
the wells and the color changes after adding acidic stop solution. The indensity is oroportional to the amount of Human vWF bound and measured at 450nm±10nm.
2.
Reagents and Materials Provided Quantity
Composition
Quantity
1
Sample Diluent Buffer
2 X 15ml
Standards
2
ABC Diluent Buffer
1 X 12ml
Detection Antibody
1 X 135ul
Antibody Diluent Buffer
1 X 12ml
Avidin-Biotin-Peroxidase
1 X 140 ul
TMB stop solution
1 X 10ml
TMB color developing reagent A
1 X 10ml
ELISA Special TBS Diluent
1 X 20ml
TMB color developing reagent B
1 X 1 . 5 ml
Instruction manual
1
Composition
Pre-coated Microliter plate,
96 wells
Complex(ABC) 1:100
()te: Standard : Frozen dried, TMB color developing reagent A : Avoid light
3. Materials Required But Not Provided Microliter plate reader in standard size.
�
Polypropylene tubes for diluting and aliquoting standard. Distilled or deionized water. Calibrated, adjustable precision pipettes. preferably with disposable plastic tips .
5. Storage and stabil ity All the components in the kit can be stored up to 1 year at -20°( and 4 weeks at 2-8°(.
Please avoid repeated freeze-thaw cycles and do not mix reagents from different kits unless they have the same lot numbers.
6. Reagents Preparation
CD
Plate washing
Discard the solution in the plate without touching the side walls. Blot the plate onto paper towels or other absorbent material. Soak each well with at least 0.35 ml PBS or TBS buffer for 1-2 minutes ,then discard the rinse solution. Repeat this process t for several times.
� Sample Preparation and Storage
Store samples to be assayed within 24 hours at 2-8°C. For long-term storage, aliquot and freeze samples at -20°C. Avoid repeated freeze-thaw cycles. Cell
culture
supernate,
tissue
lysate or body
fluids:
Remove particulates by
centrifugation, analyze immediately or aliquot and store at -20°C Serum: Allow the serum to clot in a serum separator tube (about 2 hours or 4°C) at room temperature. Centrifuge at approximately 1 000 X g for 1 0 min. Analyze the serum immediately or aliquot and store frozen at -20°C. Plasma: Collect plasma using heparin, EDTA, citrate as an anticoagulant. Centrifuge for
1 5 min at 1 000 x g within 30 min of collection. Analyze immediately or aliquot and store frozen at -20°C . Sample Dilution Guideline
User needs to estimate the concentration of the target protein in the sample and select proper dilution factor so that the diluted target protein concentration falls near the middle of the linear regime in the standard curve.
nore than 2 dissolve the
1000
,pg/mL
500
pg/ml
250
pg/ml
125
pg/ml
62.5
pg/ml
31.2
pglml
1S.6
pglml
Address: Room 605, KaiCheng Building1,QingYuanXili,QingHe,HaiOian District, BeiJing . China Tel:+86-10-59871930/59871931
Fax:+86-10-59871932
Website:'MW<. biotechist.com
3fflRSSRY .\i
S ; (;
E D I C .\ L .\ S S \ \"
25
50
ng/ml
ng/ml
12.5
ng/ml
6.25
ng/ml
3.125
ng.ml
1.56
ng/ml
0.78
ng/ml
B. Preparation of biotinylated anti-Human vWF antibody working solution: The solution should be prepared no more than 2 hours prior to the experiment. a.
The total volume should be: 0 . 1 ml/well x (the number of wells). (Allowing 0 . 1 -0.2 ml
more than total volume)
b Biotinylated anti-Human vWF antibody should be diluted in 1 :99 with the antibody
diluent buffer and mixed thoroughly.
C. Preparation of Avidin-Biotin-Peroxidase Complex (ABC) working solution: The solution should be prepared no more than 1 hour prior to the experiment. a.
The total volume should be: 0.1 mllwell x (the number of wells). (Allowing 0 . 1 -0.2 ml
MOre than total volume)
:�. Avidin-Biotin-Peroxidase Complex (ABC) should be diluted in 1 :99 with the ABC
c=lution buffer and mixed thoroughly.
:> Preparation of TMB working solution: transfer 9 volumes of TMB color developing
""eagent A in one volume of TMB color developing reagent 8 for 30 minutes in 37°( before ...sing to make TMB substrate, mixing thoroughly.
i. Assay Procedure �e
user should decide sample dilution fold by crude estimation of Human vWF
�ount in samples. Aliquot 0 . 1 ml per well of the grades Human vWF standard solutions into the precoated
96-well plate. Add 0. 1 ml of the sample diluent buffer into the control well .
Add 0.1 ml of each properly diluted sample of sera, plasma, body fluids, tissue lysates or cell culture supernatants to each empty well. Seal the plate with the cover and incubate at 3rC for 90 min. Remove the cover, discard plate content, and blot the plate onto paper towels or other absorbent material. Do NOT let the wells completely dry at any time, washing twice.
Add 0.1 m l of biotinylated anti-Human vWF antibody working solution into each well Address: Room 605,KaiCheng Building1,QingYuanXili,QingHe,HaiDian District, BeiJing , China Tel:+86-10-59871930/59871931
Fax. +86-10-59871932
Website:www.biotechist.com
3fflRSSR'I and incubate the plate at 3rC for 60 min.
®
Wash the plate three times with 0.01 M TBS or 0.01 M PBS, and each time let washing buffer stay in the wells for 1 min.
®
Add 0 . 1 ml of prepared ABC working solution into each well and incubate the plate at
(i)
Wash plate 5 times with 0.01 M TBS or 0.01 M PBS, and each time let washing buffer
®
3rC for 30 min.
stay in the wells for 1-2 min.
Add 0.09 ml of prepared TMB color developing agent into each well and incubate
plate at 3rC away from light, observe the color at all times, when shades of blue can be seen in the wells with the three-four most concentrated Human vWF standard solutions; the other wells show no obvious color, Add 0.1 ml of prepared TMB stop
solution into each well. The color changes into yellow immediately.
®
Read the 0.0. absorbance at 450nm in a microplate reader within 30 min after adding the stop solution.
@
The standard curve can be plotted as the relative 0.0.450 of each standard solution (Y) vs. the respective concentration of the standard solution (X). The Human vWF concentration of the samples can be interpolated from the standard curve.
Summary
Prepare reagents, samples and standards
�
Add prepared samples or standards and incubate the plate at 3rC for 90min, wash
plate twice with TBS
-l.
Add biotinylated antibodies and incubate the plate at 37"C for 60min, wash plate 3 times with TBS or PBS
!
Add ABC working so
on and incubate the plate at 3TC for 30 min, wash plate five
times with TBS or PBS Add TMB color dev
e!
ng agent and incubate at 37'C
-�
Add TMB stop solut1on
�
. " h "m 30 mm Read the 0.0. absorbance at 450nm w1t
�
Calculate the Human vWF concentration in the samples by plotting gragh between _oocentration and corresponding absorbances of Standard
For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS 13) concentrations in cell culture supernates, serum, and plasma.
,I
This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures.
llfiiUIItlll l lllfl
A!JAM II:! I� (A Olllntoglln Ail� MotalloproliJinnse wltfl rt"ombospenuln tYJ'.lO 1 motif, , 3), olso known as von Willebrand factor (vWF)-cleaving protease, belongs to the ADAMTS superfamily
TABLE OF CONTENTS
PAGE
SECTION INTRODUCTION
of secreted multidomain zinc metalloproteases. Full-length human ADAMTS 1 3 contains 1 427 amino acid residues that are organized into the following domains: signal peptide, pro peptide, catalytic, disintegrin-like, thrombospondin type 1 (TS Pl ), cysteine rich, spacer, seven TSP1 repeats, and two CUB domains. The propeptide contains a furin cleavage consensus motif and
is most likely removed in the Golgi or at the cell surface, releasing the 1 9 0 kDa active enzyme (1-4). ADAMTS 1 3 is mainly produced by the liver and circulates i n the blood (5). vWF, the only known substrate for ADAM TS 13, is a large rnultimeric glycoprotein that is
required for platelet adhesion and thrombus formation ( 1 , 2, 6). The hemostatic potential of
vWF increases with its length. ADAMTS 1 3 cleaves the ultra-large multimeric vWF (UlvWF)
within the A2 domain between Tyr1 605 and Met1 606, generating smaller, less adhesive multlmers (1, 7). Shear stress is required to induce a conformational change in the UlvWF fibers
to expose the cleavage site (8). I n addition to its role in platelet adhesion, ULvWF has been
shown to promote leukocyte adhesion and extravasation duri ng inflammation (9). By cleaving ULvWF, ADAMTS1 3 down-regulates not only thrombosis but also inflammation. As a result,
decreased ADAMTS1 3 activity accelerates inflammatory diseases and is associated with acute and chronic innammation (9, 1 0). ADAMTS 13 deficiency as a result of hereditary gene mutations or inhibitory autoantibodies to A DA MTS 13 is a cause of thrombotic thrombocytopenic purpura
(TTP),
which is a rare condition
of the blood-coagulation system. TTP is characterized by extensive formation of microthrombi
in the microvasculature and may be accompanied by neurological dysfunction and renal failure ( 1 1 · 1 5). Additional pathologies associated with decreased circulating ADAMTS1 3 include liver
10 10
cirrhosis, sepsis, alcoholic hepatitis, and acute pancreatitis (1 6-1 9). Low plasma ADAMTS 1 3 is a useful predictor of cardiac and cerebrovascular events in coronary artery diseases (20, 21). After acute myocardiill infarction, early decrease of ADAMTS 1 3 levels is a predictor offuture thrombotic events (22). In atrial fibrillation (AF). ADAMTS 1 3 level in patients after treatment with cardioconversion is useful for prediction of recurrence of AF (23). The Quantikine Human ADAMTS1 3 Immunoassay is a 4.5 hour solid-phase ELISA designed to
MANUFACTURED AND DISTRIBUTED BY:
USA & Canada I R&D Systems, Inc. 614 McKinley Place NE, Minneapolis, MN 5541 3, USA TEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656·4400 E-MAIL: [email protected]
CHO cell-expressed recombinant human ADAMTS13 and has bee'n shown to accurately quantitate the recombinant factor. Results obtained using natural human ADAMTS1 3 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human ADAMTS1 3.
DISTRIBUTED BY:
UK & Emope I R&O Systems Europe, lid,
19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UK
TEL: +44 (0)1 235 529449
measure human ADAMTS 1 3 in cell culture supernates, serum, and plasma. It contains
Store the unopened kit at 2-s• C. Do not use past kit expiration date.
PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for ADAMTS1 3 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any ADAMTS1 3 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for ADAMTS1 3 is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution Is added to the wells and color develops in proportion to the amount of ADAMTS1 3 bound in the initial step. The color development is stopped and the intensity of the color is measured.
LIMITATIONS OF THE PROCEDURE · FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
· The kit should not be used beyond the expiration date on the kit label.
· Do not mix or substitute reagents with those from other lots or sources. If samples generate values higher than the highest standard, further dilute the samples with
•
Calibrator Diluent and repeat the assay.
· Any variation in standard diluent, operator, pi petting technique. washing technique, incubation time or temperature, and kit age can cause variation in binding.
•
This assay is designed to eliminate interference by enzymes, proteinS, and other factors present in biological samples. Until these factors have been tested 1n the Quantikine
••
�iitr, .,
;
,
,
.·
D E SCRIPTUiN
ST�]!�GE O.f,OPENED/
(12 stri ps of8 wells) coated with a mouse
the desiccant pack. Reseal along entireedge of zip·
0
ADAMTS13
' - PA RTf
894000
Microplate
.
96 wel l polystyrene microplate
monoclonal antibody against AOAMT51 3. Conjugate
894001
ADAMTSB
894002
Assay Diluent
895881
AOAMTS13
Standard
RD5·26 Concentrate
Wash Buffer
Concentrate Color Reagent A (oiQr Reagent 8 Stop Solution Plate Sea lers
Return unused wells to the foil pouch containing
seal. May be stored for up to 1 month at 2·8· C.'
ADAMTS1 3 conjugated to horseradish
R01·89
Calibrator Diluent
21 ml ofpolyclonal antibody against
RECQHSTITUTEO MATERIAl
peroxidase with preservatives.
100 ng of recombinant human ADAMTS 13
in a buffer with preservatives; lyoph1lized. 11 ml of a buffered protein base with
preservatim.
895525
895003 895000
21 ml of a concentrated buffered protein base with presmatives.
May b€ stored for up to 1 month at H' C. •
21 ml of a 2S·fold concentrated solution of buffered surfactant with pteservatives.
125 ml of stabilized hydrogen perox1de.
895001
12.5 ml of stabilized chromogen
895031
6 ml of l N sulfuric acid.
(tetramethylbenzidine).
N/A
sive stnps.
4 adhe
d1d thiS is within the e�prration date of the kit.
Immunoassay, the possibility of interference cannot be excluded.
TECHNICAL HINTS s, always avoid foaming. · When mixing or reconstituting protein solution between additions of each standard level, ·To avoid cross-contamination, change pipette tips s. Also, use separate reservoirs for addition between sample additions, and between reagent
•
each reagent. sealers during incubation steps is To ensure accurate results, proper adhesion of plate necessary.
second soak period following the ·When using an automated plate washer. adding a 30 degrees between wash steps may addition of Wash Buffer, and/or. rotating the plate 180
improve assay precision. to the plate. Keep Substrate Solution · Substrate Solution should remain colorless until added from colorless to gradations of blue. change should Solution protected from light. Substrate
same order as the Substrate Solution. The · Stop Solution should be added to the plate in the yellow upon addition of the Stop Solution. to blue from turn will wells the color developed in Solution has not mixed thoroughly with Wells that are green in color indicate that the Stop the Substrate Solution.
For research use only. Not for use in diagnostic procedures.
dum. For research use only. Not for use in diagnostic proce
OTHER SUPPLIES REQUIRED
REAGENT PREPARATION
Bring all reagents to room temperature before use.
· Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
• Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix
· Pipettes and pipette tips. · Deionized or distilled water. · Squirt bottle, manifold dispenser, or automated microplate wa she r. ·
•
500 ml graduated cylinder.
Horizontal orbital microplate shaker (0.1 2" orbit) capable of maintaining a speed of
500 ± 5 0 rpm.
· Test tubes for dilution of standards and samples. · Human ADAMTS1 3 Controls (optional; available from R&D Systems).
;
.
gently until the crystals have completely dissolved. Dilute 20 mL ofWash Buffer Concentrate into deionized or distilled water to prepare 500 ml of Wash Buffer.
Substrate Solution · Color Reagents A and B should be mixed togethe r in equal volumes within 1 5 minutes of use. Protect from light. 200 �-tL of the resultant mixture Is required per well. Calibrator Diluent RDS-26 (1 X ) · Dilute 1 0 ml of Calibrator Diluent RDS-26 Concentrate into
30 ml of deionized or distilled water to prepare 40 mL of Cal ibrator Diluent RDS·26 (1 X). ADAMTS1 3 Standard - Reconstitute the ADAMTS1 3 Standard with 1.0 mL deionized or
distilled water. This reconstitution produces a stock solution of 100 ng/mL. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 5 minutes. Mix
PRECAUTION The Stop Solution provided with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.
SAMPLE COLLECTION & STORAGE
Cell Culture Supernates · Remove particulates by centrifugation and assay immediately or
well prior to making d ilutions.
Pipette 500 J.ll of Calibrator Diluent RDS-26 (lX) into each tube. Use the stock solution to
produce a dilution series (below). Mix each tube thoroughly before the next transfer. The ..
50 ng/mL standard serves as the h igh standard. Calibrator Dtluent RDS-26 (1 X) serves as the
zero standard (0 ng/mL).
aliquot and store samples at s -20•C. Avo id repeated freeze-thaw cycles.
Serum · Use a serum separator tube (SST) and allow samples to clot for 30 minutes before
centrifugation for 1 5 minutes at 1 000 x g. Remove serum and assay immediately or aliquot and store samples at s -20• C. A void repeated freeze-thaw cycles. Plasma · Collect plasma using heparin, EDTA, or citrate as an anticoagulant. Centrifuge for
1 5 minutes at 1000 x g within 30 minutes of collection. Assay imm ediately or aliquot and store
samples at s -20• C. Avoid repeated freeze-thaw cycles.
SAMPLE PREPARATION Serum and plasma samples require a 100-fold dilution. A suggested 1 00-fold dilution is 1 0 ).!L of sample + 990 1-1L of Calibrator Diluent RD5-26 (1 X).
4
For research use
only. Not to'(use in di gnosti procedures. a
c
(oo:!
500 !JL
�
500 !JL
500 Ill
soo Ill
5001Jl
� � � �
500 !Jl
�
�� A� N
.: ••
100 ng/ml
5 0ng/ml
, 25 ng/ml
125 og/ml
6.25 og/ml
3.13 og/ml
1.56 ng/ml
For research use only. Not for use in dlagno stic procedures.
0.781 ng/ml
HIIIIU
lll lltu t..tl 1••v..mt oml Uhtpl••' 'u ruu111 tlllnp•rilturo uofo r u Ulu. lt Is reco mmonded thl\l all samples, controls, and standards be a$f111yed In duplicate.
CALCULATION OF RESULTS
Average the duplicate readings for each stand average zero standard optical density (0.0.).
1 . Prepare all reagents, working standards, and samples as directed In the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
1.
3. Add 100 !J.L of Assay Diluent RD1-89 to each well. 4. Add 50 !J.l of Standard, control, or sample• per well. Cover with the adhesive strip provided. Incubate for 2 hours at room temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 500 ±50 rpm.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (400 J..�L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels. 6. Add 200 f!L of ADAMTS 13
Conj ugate to each
well. Cover with a new adhesive strip.
Incubate for 2 hours at room temperature on the shaker.
are capable of generating a the data using computer softw Create a star.dard curve by reducing standard curve by plotting a -fit. As an alternative, construct four parameter logistic (4-Pl) curve entration on the x-axls conc the st again s ndard on the y-axl the mea n absorbance for each sta may be linearized by the points on the graph. The data and draw a best fit curve through 0.0. and the best fit line the of log 1 3 concentrations versus the plotting the log of the ADAMTS adequate but less an uce prod will e edur proc analysis. This can be determined by regression precise fit of the data. the standard curve must be the concentration read from If samples have been diluted, multiplied by the dilution factor.
for demonstration on ly. A This stan dard curve is provided ed. assay fo each set of samples
TYPICAL DATA
at room temperature. 9. Add SO !J.l of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color In the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a
microplate reader
set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. l f wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at
450 nm. This subtraction will correct for optical imperfections in the plate. Readings made di rectly at 450 nm without correction may be higher and less accurate.
rated standard curve should be gene
r
7. Repeat the aspiration/wash as in step 5, 8. Add 200 fll of Substrate Solution to each well. Protect from light. Incubate for 30 minutes
subtract the ard, control, and sample and
tnglmll 0
10 -r--
'Ll
•
0.01
0.1
/ 1
human AOAMTS13
10
Con<entrotlon (ng/ml)
3.1 3
0.055
o.oss
0.086
0.072
0.161
0.147
0.306
0.292
1.221
1.207
QW
0.302 Ol10 0.603 n � Q 1.212
6.25
12.5 25
so
0.054
�w 0.1 59
1.56
100
Av�rag� 0.014
om
0.761
.
1,ll0 2.l96
2.410
*Serum/plasma samples require dilution. See Sample Preparation section.
for research use only. Not for use in diagnostic procedures. For research use only. Not for
use in
Corrected
Q,Q. 0.01 3 Q.0}4
diagnostic' procedures.
0.608 2.403
0.041
0.594
2.389
>�••111)1 l'�tu htutt (J'I•••IIII.III \,•ttlllll rtii iii•IIY ) I hrcc $l'ltn ples of known conccntrotlon were tested
l1111"
twenty times on one plate to assess Intra·
assay precision.
Inter-assay Precision (Precision betwe en assays) Three samples of known concentration were tested assay p recision.
- ---l< � � �•.;�;;;._<-�1- · Sample
n
Mean (ng!mL)
I I
·' · �::.; lntra·ASjl s f.f�CisJoi) 2 I I 20 I 20
- --·
Standard deviation
CV(%)
:- ;J, W
_, , . ·
I
· ·
.
W
13.8
29.7
0.177
0.364
0.685
0.256
2.3
5.7
2.6
4.51
-
W
14.2
I
o.m 5. I
with values within the dynamic range of the assay. ..
� -Assar � e
I
LINEARITY To assess the linearity of the assay, samples containing and/or spiked with high concentrations of ADAMTS 1 3 were serially diluted with Calibrator D iluent RDS-26 (1 X) to produce samples
in twenty separate assays to assess inter·
4.78 3.7
.I
W
30.2 1.08
36
RECOVERY The recovery of ADAMTS1 3 spiked to levels throughout the range of the assay in various matrices was evaluated.
SENSITIVITY Twenty assays were evaluated and the minimum detectable dose (MOD) ranged from 0.010-0.260 ng/ml. The mean MOO was 0.104 ng/ml. The M O D was determined by adding two standard deviations to the mean optical density
value of twenty zero standard replicates and calculating the corresponding concentration.
CALIBRATION This immunoassay in calibrated against a highly purified CHO cell-expressed recombinant human ADAMTS\3 (amino acids Gln34-Thr1427; Accession II Q76LX8}.
SAMPLE VALU ES Serum/Plasma - Sam ples from apparently healthy volunteers were evaluated for the presence
of ADAMTS13 in this assay. No medical histories were available for the donors used in this study.
;::sV�'PI:�)y)le): Serum (n,3Sl
for research use only. Not for use in diagnostic procedures.
Cell Culture Supernates • Aliquots of cell culture supernates from 16 various cell lines were assayed for levels of natural ADAMTS1 3. All samp les measured below the lowest standard, 0.781.ng/ml.
�nr r o�ra!llrl'h rt cA nn lv
�nt fnr II (P in rliannn
tJ• U!l l l Y
1 Ilia IIUI!y rtcounlnl rttornblnllnl nnd nnlutul hurntln ADAMI!II J. 1ho ltlctorJ llsrtld below
were prepared at 500 ng/ml In Calibrator Diluent RD5-26
(l X) a nd assayed for cross-reactivity.
Preparations of the following factors at 500 ng/ml in a mid-range recombinant human
ADAMT$13 control were assayed for interference. No significant cross-reactivity or interference was observed.
Recombinant human:
ADAMT$1
ADAMTS12
ADAMTS4
ADAMTS15
ADAMT$5
TIMP-3
ADAMT$1 0
Natural proteins:
human von Wlllebrand Factor (vWF)
vWF-A2
This immunoassay also recognizes a tru ncated version of recombinant human ADAMTS13 (amino acids Gln34-Trp688; Accession # NP_620594).
•110.10 ID i:!:•!JM:'i'�i' c- r t .? l d" 1 � !.:i "•t !100 1f'-tl ��"p I r,.QOO-m.IJ
,.
_,
i I
i
I
KC4 Page 3
ocoi Name:
C:\KC4 3.03 . . .\P-SELECTIN\cfr. Eko Adi.prt
ta Name:
C:\KC4 3.03 . . .\P-SELECTIN\dr. Eko .Adi.pia
-dini! Dateffime:
02/18/20·13 ·J4:"13:03
Repm1 Date/Time:
02/"18/20"1 3 "14:22:·1 7
ta-dr::ttions :;s3=3 3�15 ..35"'!7
'037 -�45 _a;;
--:3"3il �
! I
2
8
29.93$
3.86 :37
I i !I 3.32[!4 i I
I I I
10.162
1D289
C.352J C.1�
l
I l
_I !
I C.04SSS !I II <(}
J3
ii.SCS
3_7�
4
i ! I
b
.:.j,_i..i,.'j(
4.7034
6.:�273
21/£27
I
!
�
7
12.526
2.nSJ
I $.812Il
4.7;].4
1.6707
3.076)
13.217
8.S76D
3.6718
4.4313
634/J�
1.3551
sssoo
18.4>-s
=>31.�o(J{J
"14.356
S.SiiJO
2.63D1
:ZS.11Jl5
7.4319
5.1390
8.9211
7.37/6
;;.m)S m.46S Zl.W
i.�.lJ4 i
43347
!
6.4270
! ;
2.3613
1 !
I
Zl.234
5.2353 2.00S1
�
u
1()
11
12
3.737)
6.2755
18.110
Z3.794
;:,:3341
5.�35
8.6771
15.796
20.W3
1.4533
1334;
35423
:,!J1.�olHJ
17.347
:1.3330
15.613
S.DIJS:3
2.4734
IJ.SSSll
12562
I
1S.7C3
3.9�
2.1691
ZS1S8
43'571
5.1H::i
16.3il3
10.011
i.n16
2.�78
24A94
5.411!]
S.3S21
5.973"3
2.57" 27
II
4.8183
11.746:
6.31l!S
5.47!0
�-7�
i
I
Il I
I
I
! I I I
I
---
,.,...-
'
.
PERJANJIAN KERJASAMA ANTARA BADAN PENELfTIAN DAN PENGEMBANGAN KESEHATAN KEMENTERIAN KESEHATAN RI DAN FAKULTAS KEDOKTERAN UNIVERSITAS DI PQNEGORO TENTANG R!SET PEMBINAAN ILMU PENGETAHUAN & TEKNOLOGI KEDOKTERAN (R!SBIN I PTEKDOK)
A �
HK.06.0 1 / 1 / 1696/ 2 0 1 2 Nomor : l l 08J UN7.3.4/D/KS/20 l 2 Nomor :
bulan
Pada hari ini Kamis tanggal satu
Maret
tahun dua ribu dua betas,
kami yang bertandatangan di bawah ini :
1 . d r. Trisa Wahyuni Putri,
MKes :
Badan Pe nc l itian dan Pengembangan Kesehalan Kementerian Kesehatan Rl bcrkedudukan dan berkantor di Jalan Percetakan Ncgara Nomor 29 J aka rta 1 0 560, dal am hal ini Pejabat
Pembuat
Komitmen
bertindak dalam jabatannya untuk dan atas nama Badan Penelitian dan Pengembangan
2.
Kesehatan,
selanjutnya disebut PII-IAK
KESATU;
dr. Endang Ambarwati, Sp. KFR :
Dekan Fakultas Kedokteran Universitas Diponcgoro,
berdasarkan surat pendelegasian dari Rektor Universitas Diponegoro ·Nomor 12 78jU N7. PfTU / 20 1 2 tanggal 29 Feb rua ri 20 1 2 dalam hal ini bertindak untuk dan atas nama Universitas Diponegoro yang d i tetapkan sebagai Badan Layanan Umum Penuh rnelalui Kepmenkeu Nomor 259/ KMK.OS/2008, tanggal 15 Se p te mbe r 2008 bcrkedudukan di Jalan Dr.Soetomo
No.
18
(Komplek
Semarang selanjutnya disebut
PIHAK KESATU PARA PIHAK, telah Badan Penelitian
Zona
Pendidikan
RSUP
Dr.
Kariadi)
PIHAK KEOUA.
PlHAK KEDUA selanjutnya bersama-sama disebut sepakat untuk mengada k an Perjanjian Kerjasama antara dan Pengembangan Kesehatan dan Fakultas Kedokteran dan
Universitas Diponegoro dengan ketentuan dan sya.rat-syarat sebagai berikut:
1
l
PASAL DASAR DAN TUJUAN ( 1 ) Perjanjian ini dibuat berdasarkan referensi yang meru pakan bagian yang tidak terpisahkan dari perj a njian ini, yaitu : a. Undang-Undang Nomor 18 Tahun 2002 tenl,ang Sistern Nasional Penelitian, Pengembangan dan Pencrapan llmu Pengetahuan dan Teknologi (Lem baran Negara Republik lndonesia tahun 2002 Nomor 84, Tambahan Lembaran Negara Republik Indonesia Nomor 4 2 1 9 ) ; b . Undang-Undang Nomor 2 0 Tahun 2003 tentang Sistem Pendidikan Nasion
Penelapan Tim Pelaksana
(2) Perjanjian 1111 bertujuan untuk mernperbaiki dan membina Indones� dengan menggerakkan, iptekdok pem bangu nan mendayagunakan, dan meningkatkan kemarnpuan ilmiah yang ada untuk ikut serta memanfaatkan, mengembangkan, dan menguasai ilmu pengetahuan dan teknologi yang diprioritaskan dalam bidang riset dan teknologi serta pencapaian sasaran pembangunan bidang kesehatan.
2
PAS!\L :2 l�UANG LINGKUP Ruang lingkup perjanjian meliputi pelaksanaan kegiatan penelitian, pembiayaan, jangka waktu pelaksanaan, tata cara pembayaran, hak dan kewajiban, pcngadaan barangjjasa, laporan, hak atas kekayaan inlclektual, sa.nksi, keadaan rnemaksa, dan penyelesaian persclisihan. PASAL 3 KEGIATAN PENEL!TIAN ( 1} Pcnelilian Riset Pcm binaan Llmu Pcngetahuan dan Teknologi T<edokteran diarahkan untuk peningkatan kesehatan ibu, bayi dan balita, pcrbaikan status gizi masyarakat, pengendalian penyakit menular serta penyakit tidak menular, diikuti penyehatan lingkungan. (2) Protokol penelitian yang dibiayai oleh PIHAK KESATU merupakan protokol yang telah lulus dalam seleksi panel. (3) Protokol penelitian sebagaimana dimaksud pacta ayat (2) tercanlum dalam lampiran perjanjian ini dan merupakan bagian yang tidak terpisahkan. (4) Tim penelili sebagaimana tercanturn dalam lampiran perjanjian ini tidak diperkenankan untuk diganti/ diu bah tanpa persetujuan PIHAK J<ESATU, dan merupakcm bagian yang tidak terpisahkan dari perjanjian 1111.
(5) Pengganlian dan atau perubahan tim peneliti sebagaimana dimaksud pada ayat (4) harus di ajukan secara Le rtulis dengan melampjrkan persetujuan tenulis dari kctua panel pakar dan amandemen etik. PASAL 4 PEMBlA YAAN ( 1 ) Bantuan dana diberikan dalam bentuk swake lola . (2) Biaya pclaksanaan kegiatan yang diberikan oleh PIHAK KESATU kepada PIHAK KEDUA dengan rincian sebagaimana tercantum dalam lampiran perjanj ian ini dan merupakan bagian yang tidak terpisahkan. (3) Biaya pelaksanaan kegiatan penelitian sebagaimana dimaksud pada ayat { 1 ) sebesar Rp. 7 2 1 .599.000,- (Tuju h Ralus Dua Puluh Satu Juta Lima I�alus Sembilan Puluh Sembilan Ribu Rupiah) sudah termasuk PPh dan PPN, yang dibebankan pada DIPA Sekretariat Badan Penelitian dan Pengembangan Keschatan Tahun 2 0 1 2 . (4) Biaya sebagaimana dimaksud pada ayat (3) meliputi segala pengeluaran dalam pclaksanaan kegiatan penelitian termasuk pajak-pajak, materai
3
7
dan b iaya biaya lainny<J l w rus Jilm_yar- .olcll t >f t l A K K I � D U /\ sesum de ngan kcte ntuan ya ng bcrla k u {5) Peneliti sebagaimana lercanlum dalam la m p ira n perjanjian ini tidal< diperkenankan unluk me ngaj u kan pe mb iayaa n kepada pihak lain dalam rangka pe ne l i ti a n yang sama. (6) P lf-!A [( I<EDUA tidak cliperkenankan untuk m e n gali hk a n dan atau meminclahtangankan se ba gian maupun seluruh k'egialan penelitian s e ba gaim ana ter-cantum dalam la rn pi ran perjanjian ini ke pad a pihak lain ta n pa perselujuan P ! H A K r<ESATU. -
.
PASAL
5
JANGKA WAKTU
( 1) Pelaksanaan kegiatan penelitian scbagaimana terse but dalam perj anj ian ini dil ak uka n selama 1 0 { se p ul u h) bula n kale nder terhit u ng sejak penandatanganan perj a nji a n in i {2) Ap a b i l a pelaksanaan kegiatan p e ne li tian ini tidak se le sai dalam waktu yang telah ditetapkan scbagaimana disebut pacta aya t { 1 ) , malca sisa dana clikembalikan ke Kas Negara. .
PASAL
6
TATA CARA PEMBAYARAN
( 1 ) Pe nya l u ran dana oleh PIHAK KESATU kepada Pll i AK KEDUA dilaku ka n melalui transfer kc rekening resmi insti tu si PARA PIHAK ya itu : Nama f<eke n i n g : Penampungan TDPT Nomor Rc ke n ing : 0 1 1 3 1 47606 Bank : BNf : UNDI P Cabang (2) Ta ta cara pcn cai ran dana pe ne li ti a n sesuai dengan ketentuan yang berlaku dan Pedoman Administrasi K euan gan R isb in l ptekdok 2 0 1 2 . (3) Penyaluran dana se ba ga iman a dimaksud pacta ayat ( 1) tidak bedak u untuk belanj a sewa dan b clanj a bahan habis pakai yang mekanisme me la lui Panitia d an j atau Pejabat Pe ngadaan pelaksanaannya Baran g/ J asa (4) Pe nya l u ra n dana sebagaimana dimaksud pacta ayat (3) dilakukan melalui rekening pe nye dia barangjjasa. (5) Pe n gg u na an dana p e nel i tian harus disetuj u i j diketahui olch P£HAK .
KEDUA.
{6) PIH AK
KESATU
pencairan
mengirimkan
bukti-bukti
KEDUA setelah
penyaluran
bukti-bukti pajak yang telah disetor proses pencairanj p e m baya ra n se le s a i .
se rta
4
danajb ukti
kepada
PIHA K
� ;y
�
PASAL 7 HAK DAN KEWAJlBAN ( 1 ) PIHAK KESATU
a.
Hak :
1 ) Memperoleh l apo ran a kh i r abs tra k da n t;asil pelaksanaan pene litia n dari PIH.AK KEDUA da lam bentuk h a rdc op y dan s oftco py ; 2) Mempe roleh raw data (data mcnlah) hasil penelitian dari PI H A K K ED UA ; 3) Me m pe ro le h semua d ok u me n asli yang be rka itan dengan pertanggungjawaban ke ua ngan dari PIHAK KEDUA s elam bat lambatnya awal bu lan Desembcr 2 0 1 2 . b. Kewajiban: M el aku kan pe m bay a ra n pelaksanaan kegiatan penelitian kepada PIHAK KEDUA me la lui rckening resmi institusi sesuai dengan usulan yang telah diterima oleh PIHAK KESAT U . ,
-
(2)
PIHAK KEDUA
a . H ak
:
Menerima pembayaran atas pclaksanaan kegiatan peneli tian dari PIHAK KESATU sesuai dengan usulan yang Lelah diserahkan oleh PlHAK KEDUA. b.
Kewajiban: 1) M el akukan pcmantauan dan evaluasi in ternal atas pelaksa n aan penelitian di i n sti tu s i ny a dan bertanggung jawab penuh atas hasil pe nel itia n ; 2) Menyampaikan laporan akhir pe n eli tia n dan abstrak kepada PIHAK KESATU sesuai de n ga n j a ngka waktu yang di sepaka ti; 3) Me nyera hka n raw data (data menlah) hasil penelitian kepada PIHAK KESATU;
scmua dokumen yang b erhu bungan dengan pelak sanaa n pe n elitian ; 5) Menyelesaikanj menyerahkan semua benluk pertanggungjawaban keuangan kep ada PIHAK KESATU sesuai kctcntuan yang berlak u
4)
Menyimpan
salinanjcopy
.
PASAL 8
PENGADAAN BARANG/JASA (1)
Pro ses Pejabat
pengadaan barangjjasa dilaksanakan oleh Panitia danjatau Pengadaan B arangj Jas a yang ditunjuk oleh PIHAK KEDUA.
5
7 ·�
/
(2) Panitia
danj a ta u
Pejabal Pengaclaan 1.:3arang/Ja::;e� se!x.tgairnana dimaksud pada ayat ( 1 ) h a t·us m emil iki serlifikat k et� h l i
9
LA PO RAN
( 1 ) PIHAK KEDUA wajib membuat dan menyampaikan la p o ra n kemajuan penelitian kepada PTHAK KESATU (minggu kedua bulan September 20 1 2 ) sebanyak 3 (tiga) rangkap.
(2) PIHAK
(3)
KEDUA waj ib mcmbuat clan menyerahkan laporan akhir penclitian kepada PIHAK KESATU selambat-lambatnya mmggu ketiga bulan Desember 2 0 1 2 sebanyak 3 ( tiga) ranglcap. Penulisan ·Laporan Akhir h a rus mengikuli ketcntu a n dalam Buku
Panduan Penyusunan Laporan Akhir Penclitian Badan Litbangkes yang diterbitkan oleh
Komisi
Ilmiah Penelitian Keschatan Badan Litba ngke s . PASAL
10
KEPEMILIKJ\N HASIL PENELITIAN
Kcpemilikan hasil penelitian yang dimaksud adalah: ( 1 ) Hak Kelayakan Intelektual, teknologi tepat guna, temuan lainnya yang di pero lah sebagai hasil pclaksanaan kcgiata n penelitian ini dan menjadi milik bersama para pi ha k (2) Dalam hal lerjacli tuntutan dari pihak lain aLas penggunaan suatu ala l atau te k no logi tertentu ak ibat penelilian ini, P!HAK KEDUA dalam rangka pekerjaan berdasarkan pcrjanjian ini akan membebaskan PIHAK KESATU dari segala tuntutan hukum pihak la i n terse bu t . PASAL 1 1
PERTUKARAN INFORMASI (1)
PARA PIHAK sepakat untuk saling bertukar data dan informasi mengenai hal-hal yang berhubungan dengan pelak sanaa n Perjanjian ini dan semata-mata hanya digunakan unluk kepentingan yang sesuai dengan maksud dan tuj uan Pe rj anjian Ke rjasam a Penelitian ini. (2) PARA PIHAK sepakat untuk menjaga kerahasiaan seluruh data dan informasi sebagaimana dimaksud pada ayat ( 1 ) dan tidak akan m e m be rikan kepada pihak ketiga tanpa pe rse tujuan tertu lis dari PARA PlHAK.
6
'
IJASJ\L 1 2 SANKS I
( 1 ) Bilamana PIHAK KEDUA clalam pelaksanaan kegiatan dan penggunaan dana tidak sesuai dengan syarat dan ketentuan yang te1·cantum dalam perjanjian ini danjatau melanggar ketentuan Peraturan Perundangan yang berlaku, PIHAK I<ESATU memberikan sanksi. berupa peringatan tertulis mulai peringatan pertama sampai dengan peringatan ketiga. (2) Pemberian sanksi sebagaimana dimaksud pacta ayat ( l ) dilakukan apabila P!HAK KEDUA berdasarkan hasil evaluasi dan verifikasi terbukli melakukan kekeliruan, baik dalam me laksanakan kegiatan maupun pengelolaan keuangan yang dapat menimbulkan kerugian Negara. (3) Apabila PI I-IAK KEDUA tidal< mengindahkan pcringatan tertulis dari PIHAK KESATU scbanyak 3 (tiga) kali sebagaimana dimaksud pada ayat ( 1 ) , maka PIHAK KESATU dapat memberlakukan sanksi kepada PIHAK KEDUA berupa: a. Menarik kembali danjatau menghentikan bantuan dana dan/atau meminta kembali bantuan dana yang telah disalurkan sesuai dengan perJanjian ini; b. Mcmasukkan PIHAK KEDUA ke dalam daftar sebagai lernbaga yang tidak rnemenuhi syarat sebagai pencrima bantuan dana Risbin Jptekdok. c. Melaporkan PIHAK KEDUA kepada lcmbaga/ instansi yang berwenang untuk proses tindak lanju t. PASAL
13
KEADAAN MEMAKSA (FORCE MAJEURE)
Keterlambata.n pelaksanaanjpenyelesaian pckerjaan yang diakibatkan oleh keadaan memaksa (force majeure) dapat membebaskan PIH AK KEDUA dari sanksijdenda scbagaimana tersebut dalam pasal 1 2 Perjanjian Kerjasarna ini. ( 1 ) Yang dimaksud keadaan rnernaksa (force majeure) adalah: a. Bencana alam (gernpa bumi, tanah longsor, banjir) dan keadaan cuaca yang tidak mernungkinkan pekerjaan dilaksanakan; b. Adanya perang, huru-hara, pemberontakan, kekacauan, kebakaran dan epidemi; c. Kejadian lain diluar kekuasaanjkemampuan manusia dan kejadian tersebut dapat dipahami/ d i setujui oleh PIHAK KESATU. (2) Apabila terjadi keadaan rncrnaksa, maka PIHAK KEDUA harus rnernberitahukan secara tertulis kepada PIHAK KESATU selambat lambatnya dalam waktu 14 (ernpat belas) hari sejak terjadinya keadaan